NewzIntel.com

Blog

  • MIL-OSI Russia: The Department of Construction Materials Technology and Metrology has developed methods to improve the fire safety of concrete

    Translation. Region: Russian Federal

    Source: Saint Petersburg State University of Architecture and Civil Engineering –

    An important disclaimer is at the bottom of this article.

    Associate Professor of the Department of Construction Materials Technology and Metrology Dmitry Panteleev completed the research work “Crack resistance of dispersion-reinforced concrete after high-temperature heating” as part of the grant competition for the implementation of research work by scientific and pedagogical workers of SPbGASU in 2025.

    Every year in Russia there are many fires in buildings and structures. Their number can be reduced by increasing the requirements for the structural safety of buildings. For this, when designing, in addition to calculating the load-bearing structure for strength, it is also necessary to carry out a fire resistance calculation to guarantee the preservation of the load-bearing capacity in fire conditions for a specified time.

    In case of fire, high fire resistance of building structures is a guarantee not only of the structural integrity of the building, but also of the safety of people. After the fire starts to affect the structure, concrete can explode, breaking off from the heated surface in plates. Pieces of peeling concrete fly off with a bang to a distance of up to 10 m.

    During the research, fibre-reinforced concrete compositions were designed and manufactured, followed by determination of their properties after exposure to high-temperature heating.

    It was found that the use of steel fiber can increase the crack resistance and fracture toughness of concrete structures, thereby making them safer in the event of a fire, while the use of synthetic microfiber helps to avoid explosive destruction.

    As a result of the research, effective versions of fiber concrete were developed using high-modulus steel and low-modulus synthetic fibers to obtain highly fire-resistant concrete, to increase their technical and economic efficiency, reliability and operational safety of building and structure structures.

    Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

    .

    MIL OSI Russia News –

  • MIL-OSI Russia: The 2nd course for Kazakh entrepreneurs has been completed in Qingdao

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    An important disclaimer is at the bottom of this article.

    Source: People’s Republic of China – State Council News

    BEIJING, July 8 (Xinhua) — The second course for Kazakh entrepreneurs was held in Qingdao, Shandong Province, east China, in late June and early July.

    The 2nd training course on regional trade and economic cooperation between agricultural enterprises of China and Kazakhstan was held at the Institute of Trade and Economics of the Shanghai Cooperation Organization (SCO) of Qingdao University. It was attended by 13 entrepreneurs from Kazakhstan, the local newspaper Dazhong Ribao reports.

    The course participants visited the SCO International Exhibition Centre, the SCO One-Stop Service Platform and local enterprises, where they learned about the development of livestock technology and China’s achievements in the application of intelligent agricultural technologies.

    In addition, last Friday the institute hosted a business meeting of entrepreneurs from China and Kazakhstan.

    “The meeting allowed us to establish contacts with several Kazakh enterprises. The parties agreed to deepen contacts to promote the implementation of agricultural investment projects in Kazakhstan,” Wang Huawei, director of investments at one of the Qingdao investment companies, told the newspaper in an interview.

    Since its establishment in 2022, the SCO Institute of Trade and Economics has conducted 175 courses, attended by 12,000 people from SCO countries and countries participating in the Belt and Road Initiative. -0-

    Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

    .

    MIL OSI Russia News –

  • MIL-OSI Russia: China’s military expresses confidence in fighting separatists seeking ‘Taiwan independence’

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    An important disclaimer is at the bottom of this article.

    Source: People’s Republic of China – State Council News

    BEIJING, July 8 (Xinhua) — China’s People’s Liberation Army (PLA) has the confidence and ability to dispel all illusions of separatists advocating “Taiwan independence,” Defense Ministry spokesman Jiang Bin said Tuesday.

    Jiang Bin thus commented, at the request of journalists, on recent statements by the head of the Taiwanese administration, Lai Qingde, about the so-called increase in the “defense budget” and the “struggle for Taiwan, Penghu, Kinmen and Matsu.”

    Both sides of the Taiwan Strait belong to China alone, and Taiwan, Penghu, Kinmen and Matsu are all part of China’s sacred territory, Jiang Bin stated.

    Jiang Bin criticized Lai Qingde for fabricating security threats to manipulate public opinion in Taiwan and attempting to militarize local society and drag Taiwan’s future into a scenario of external interference.

    Lai Qingde’s call to “fight for Taiwan, Penghu, Kinmen and Matsu” is actually a fight for the interests of the Democratic Progressive Party and the separatists’ desire for “Taiwan independence,” he confirmed.

    Commenting on Taiwan’s military exercises that will begin on Wednesday, Jiang Bin noted that no matter what exercises they conduct or what weapons they use, it will not stop the PLA’s countermeasures against “Taiwan independence” or stop the irresistible trend of national reunification. -0-

    Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

    .

    MIL OSI Russia News –

  • MIL-OSI Russia: Shanghai Welcomes Pushkin: Special Exhibition Introduces Chinese to Russian Poet

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    An important disclaimer is at the bottom of this article.

    Source: People’s Republic of China – State Council News

    SHANGHAI, July 8 (Xinhua) — A special exhibition titled “Great Poet, Pride of the Nation – A.S. Pushkin and Eastern Repercussions” opened at the China Printing and Publishing Museum in Shanghai on Monday.

    The event presents more than one hundred exhibits from the collection of the All-Russian Museum of A.S. Pushkin, which provide a comprehensive overview of the creative path of Alexander Pushkin and the dissemination of his works in China over more than 100 years. Many of them were imported to China for the first time and shown to the country’s residents.

    The exhibition consists of three parts dedicated to the poet’s biography, his classical works, and his connection with China. Pushkin’s study in the Mikhailovskoye estate, where the Russian poet created the historical drama “Boris Godunov” and other famous lyric poems, was recreated on site.

    The exhibition also features valuable works of art created by Russian artists from the late 19th to the early 21st century, such as Ilya Repin’s painting “The Duel of Onegin and Lensky,” Alexander Benois’s illustrations for “The Bronze Horseman,” and Vladimir Favorsky’s illustrations for “Boris Godunov.”

    In addition, the exhibition pays great attention to the dissemination of the Russian poet’s works and their influence in China, and presents rich literary sources, including a copy of the Shiu Bao newspaper, in which, as is known, A.S. Pushkin was first mentioned in China.

    At the same time, the exhibition also displays manuscripts and personal collections of Chinese translators, which have become important evidence of Sino-Russian literary exchanges. Among them are works and translations by Ge Baoquan, Wang Zhiliang, Feng Chun, as well as the Pushkin Medal awarded to Liu Wenfei and his award certificate.

    Museum visitors can use an interactive device to receive commemorative postcards printed with poems such as “If Life Deceives You…,” translated by Ge Baoquan, Feng Chun and Liu Wenfei.

    The exhibition opened to the public on Tuesday and runs until October 9.

    Shanghai has an inseparable connection with Pushkin. Let us recall that at the beginning of the 20th century, Pushkin’s novel “The Captain’s Daughter” was translated into Chinese and published in Shanghai. This novel became the first work of Russian literature translated into Chinese and published as a separate book, which, according to some scholars, marked the beginning of the translation and dissemination of Russian literature in China.

    Moreover, in one of the squares of the Chinese metropolis there is a monument to the great Russian poet, which was originally erected in early February 1937, restored in February 1947 and reconstructed in August 1987. -0-

    Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

    .

    MIL OSI Russia News –

  • MIL-OSI Russia: Australian Prime Minister to Visit China /detailed version-1/

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    An important disclaimer is at the bottom of this article.

    Source: People’s Republic of China – State Council News

    BEIJING, July 8 (Xinhua) — At the invitation of Chinese Premier Li Qiang, Australian Prime Minister Anthony Albanese will pay an official visit to China from July 12 to 18, Chinese Foreign Ministry spokesperson Mao Ning said on Tuesday.

    Mao Ning noted at a regular press briefing that the visit is taking place at a time when the China-Australia comprehensive strategic partnership is entering its second decade.

    “Under the leadership of the two heads of state and the joint efforts of the two sides, China-Australia relations have continued to improve,” Mao Ning said.

    “China stands ready to work with Australia to seize the upcoming visit as an opportunity to intensify exchanges, enhance mutual trust and expand practical cooperation to further advance the China-Australia comprehensive strategic partnership,” Mao Ning said. -0-

    Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

    .

    MIL OSI Russia News –

  • MIL-OSI Russia: Measures will be tough – the Central Bank warned banks against imposing conditions on deposits

    Translation. Region: Russian Federal

    Source: Mainfin Bank –

    An important disclaimer is at the bottom of this article.

    Why did complaints arise about additional conditions for deposits?

    Russian investors complain about the behavior banks, which lure customers with higher rates, but require a number of actions to be taken to obtain generous terms. Among the banks that have requirements for high rates on deposits:

    Yandex Bank – the 21% rate is valid only with the Plus subscription and once for 62 days;
    VTB – 21.5% for 3 months, available only with MiXX subscription;
    Sovcombank – a surcharge to the deposit rate of up to 4% is provided for purchases using the “Halva” card with the “Ten” subscription;
    MTS Bank – the maximum rate is provided for card transactions over 90 thousand rubles per month;
    Sberbank – the best conditions apply to “new money” that has not been stored in accounts for more than two months, as well as when connecting a subscription.

    “It is becoming increasingly difficult to simply open a deposit – clients have to study a ton of conditions and meet dozens of criteria in order to receive a favorable interest rate: at the same time, the increased rates are valid for a limited period,” the expert noted.

    Banks require depositors to connect paid subscriptions, turnover on cards, keep certain balances, receive salaries into an account – it is much more difficult to calculate the real profitability of such deposits, not to mention convenience and transparency for the client.

    How does the Central Bank of the Russian Federation plan to combat the imposition of conditions on deposits?

    The Bank of Russia is closely monitoring the situation on the savings products market – credit institutions have been recommended to honestly inform citizens about the terms and conditions and to abandon the practice of putting forward numerous requirements to receive a higher rate. If the recommendations are not followed, the regulator will have to develop amendments to the legislation or create a banking standard to restore order in the industry.

    Let us recall that the high key rate has led to a surge in the popularity of deposits – this year, balances on individuals’ accounts have grown by 6%, amounting to over 61 trillion rubles: by the end of the year, the figure could reach 70 trillion rubles. However, after the key rate was reduced (from 21 to 20%), banks began to massively revise the terms of deposits for the worse, but the demand for deposits and savings accounts remains high.

    12:00 08.07.2025

    Source:

    Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

    .

    MIL OSI Russia News –

  • MIL-OSI Asia-Pac: FS meets finance sector in Seoul

    Source: Hong Kong Information Services

    Financial Secretary Paul Chan today began his visit to Seoul, Korea, by meeting Bank of Korea Governor Rhee Chang-yong and Korea Investment Corporation President & Chief Executive Officer Park Il-young.

    Upon arrival in the afternoon, Mr Chan visited the Bank of Korea, the country’s central bank, and met Governor Rhee Chang-yong to discuss the developments in finance, trade and economic landscapes of the two places, in the region and around the globe.

    They also exchanged views on monetary and interest rate policies and investment trends.

    During the meeting, Mr Chan shared the latest developments in Hong Kong, particularly the continuous capital inflow to Hong Kong’s financial system, reflecting international investors’ confidence in Hong Kong in the current international environment.

    Mr Chan said that Hong Kong maintains a free and open economic and financial system as well as the Linked Exchange Rate System under the “one country, two systems” principle. He also highlighted that Hong Kong’s unique advantage of being connected to the Mainland and the world, as well as its highly internationalised characteristics, is further attracting more international participants and capital to enjoy opportunities brought by developments in China.

    Hong Kong’s international ties are continuously deepening, Mr Chan added.

    Thereafter, the finance chief visited the Korea Investment Corporation (KIC) and met its President & Chief Executive Officer Park Il-young to have an in-depth exchange of opinions on various issues of mutual concern, such as trends of investment markets, asset allocation strategies and digital asset developments.

    The KIC was established by the Korean government in 2005, responsible for managing part of Korea’s foreign exchange reserves and other public funds for overseas investments. Currently, over US$200 billion of assets are under its management.

    Mr Chan shared the recent developments in Hong Kong’s economic and financial markets, and its important role in connecting capital and investors from China and around the globe.

    He pointed out that Hong Kong’s capital market is closely connected to the Mainland’s innovation and technology (I&T) ecosystem. The recent stock market is vibrant, with many leading Mainland I&T enterprises having listed or planning to list in Hong Kong. To international investors, Hong Kong serves as a highly effective gateway to tap into I&T opportunities in Greater China.

    Mr Chan welcomed Korean capital to better use the Hong Kong market to allocate international investments and jointly seize the vast business opportunities of I&T developments.

    In the evening, Mr Chan had dinner with leaders in Korea’s digital asset industry, where he shared Hong Kong’s developments and opportunities in digital assets.

    He also encouraged the local industry to actively participate in the Hong Kong market and jointly explore and expand more applications and developments in digital assets.

    MIL OSI Asia Pacific News –

  • MIL-OSI Asia-Pac: Railway financial scheme approved

    Source: Hong Kong Information Services

    The Transport & Logistics Bureau and the MTR Corporation have executed the Part 1 Project Agreement, subsequent to the approval of the financial arrangement for Part 1 of the Northern Link (NOL) Project by the Chief Executive in Council today.
     
    Supported by an independent checking consultant, the Government critically examined the financial estimates provided by the corporation in relation to Part 1 of the NOL Project, and verified that the capital cost estimate is about $31.4 billion (in July prices).
     
    Noting that the NOL Project embodies significant strategic value, the Government said that it has decided to make major breakthroughs to enhance the project’s speed and efficiency.
     
    It explained that it would take forward the project through a holistic planning and staged implementation strategy, planning the NOL Spur Line in combination with the NOL Main Line as one project to achieve synergies and realise cost savings.
     
    The project would be implemented under a two-part approach to expedite progress. The execution of the Part 1 Project Agreement at this juncture could propel the project forward immediately, and in parallel carry out the detailed planning and design as well as statutory procedures for the NOL Spur Line.
     
    In the spirit of innovating continuously, the Government is pursuing various strategies for reducing cost and accelerating project delivery, which would be implemented as soon as possible.
     
    Such strategies include leveraging Mainland approaches and capabilities in construction on account of the cross-boundary element of the project, and setting up a dedicated team in the Highways Department to handle building submissions in a manner to streamline the overall project workflow and expedite procedures.
     
    These initiatives will not only improve the construction efficiency of the cross-boundary NOL Spur Line, but may also benefit the NOL Main Line to a certain extent, the Government said.
     
    By adopting a result-oriented mindset, the construction efficiency will also be improved with railway-related Mainland standards, practices and resources, substantially bringing forward the planning of the NOL Spur Line.
     
    The target is to commission the NOL Spur Line together with the NOL Main Line by 2034 or earlier, which is about two years earlier than what was originally envisaged, the Government added.
     
    The Chief Executive in Council approved the grant of sites at Kam Sheung Road Station Phase 2; Fanling North Area 13 (East) and Area 16; Kwu Tung North Area 22 (East), Area 26 (West), Area 14 and Area 15; as well as San Tin Area 4D, Area 6A and Area 2A to the MTR Corporation for residential and commercial development under the “Rail-plus-Property” model.
     
    A total fixed lump sum of $39.05 billion, in money-of-the-day prices, would be deducted from the full market value land premium of the sites assessed on a “with-railway” basis in the future as funding support to the corporation in implementing Part 1 of the NOL Project.
     
    The execution of the Part 1 Project Agreement today would immediately kick-start works that are more ready and time-critical, including the civil and structural works of two sections of the NOL Main Line from the Kam Sheung Road Station to the intersection with the approach tunnels to Ngau Tam Mei Depot and from the San Tin Station to the Kwu Tung Station.
     
    The MTR Corporation is required to carry out the detailed planning and design of the NOL Spur Line simultaneously, including statutory procedures relating to the environmental impact assessment and railway scheme gazettal, and strive for completion as early as possible.

    MIL OSI Asia Pacific News –

  • MIL-OSI USA: Two California Residents Plead Guilty in Connection with $16M Hospice Fraud Scheme and Money Laundering Scheme

    Source: US State Government of Utah

    Two California residents pleaded guilty yesterday in connection with their roles in defrauding Medicare of nearly $16 million through sham hospice companies and to laundering the proceeds of the fraud as part of a multi-year scheme.

    According to court documents, Karpis Srapyan, 35, of Winnetka, California, conspired with others, including co-defendants Petros Fichidzhyan and Juan Carlos Esparza, to bill Medicare for hospice services that were not medically necessary and never provided. To conduct their fraudulent scheme, they used a series of four sham hospice companies: one owned by Esparza and the other three owned by foreign nationals but controlled by the defendants. Srapyan and his co-defendants concealed the scheme by using foreign nationals’ personal identifying information to open bank accounts, submit information to Medicare, and sign property leases. They also misappropriated names and other identifying information of several doctors, two of whom were deceased, to fraudulently bill Medicare for purported hospice services. In total, Medicare paid the fake hospice companies nearly $16 million.

    Fichidzhyan, Esparza, and Srapyan worked with others to launder the fraudulent proceeds from their hospice scheme. Susanna Harutyunyan, 39, of Winnetka, was aware that her husband and co-defendant Mihran Panosyan was involved in illegal activity with Srapyan and Fichidzhyan. As part of the money laundering scheme, Harutyunyan and her co-defendants maintained fraudulent identification documents, bank documents, checkbooks, and credit and debit cards in the names of purported foreign owners in the residence where she and Panosyan lived and another residence that was owned in her name. Srapyan conducted dozens of financial transactions, totaling approximately $3.2 million, moving funds between accounts in the names of the sham hospice companies, accounts in the names of foreign nationals that were controlled by the defendants, and other accounts involved in the money laundering scheme. Harutyunyan knowingly spent fraudulent proceeds on personal expenses, including payments for a BMW automobile.

    Srapyan pleaded guilty to conspiracy to commit health care fraud and money laundering and is scheduled to be sentenced on Oct. 6. He faces a maximum penalty of 20 years in prison. Harutyunyan pleaded guilty to money laundering and is scheduled to be sentenced on Nov. 17; she faces a maximum penalty of 10 years in prison. A federal district court judge will determine their sentences after considering the U.S. Sentencing Guidelines and other statutory factors. Harutyunyan faces deportation.

    Co-defendant Petros Fichidzhyan previously pleaded guilty to health care fraud, aggravated identity theft, and money laundering. In May, Fichidzhyan was sentenced to 12 years in prison. Co-defendant Mihran Panosyan pleaded guilty to money laundering in June and is scheduled to be sentenced Sept. 8. Co-defendant Juan Carlos Esparza’s change of plea hearing is scheduled for July 14.

    The guilty pleas today are the most recent convictions in the Justice Department’s ongoing effort to combat hospice fraud in the greater Los Angeles area. Last year, a doctor was convicted at trial for his role in a scheme to bill Medicare for hospice services patients did not need, and two other defendants were sentenced for their roles in a hospice fraud scheme.  

    Matthew R. Galeotti, Head of the Justice Department’s Criminal Division, Assistant Director in Charge Akil Davis of the FBI Los Angeles Field Office, and Deputy Inspector General for Investigations Christian J. Schrank of the U.S. Department of Health and Human Services Office of the Inspector General (HHS-OIG) made the announcement.

    The FBI and HHS-OIG are investigating the case.

    Trial Attorneys Michael Bacharach, Sarah E. Edwards, and Allison L. McGuire of the Criminal Division’s Fraud Section are prosecuting the case, and Assistant U.S. Attorney Tara B. Vavere for the Central District of California is handling asset forfeiture.

    The Fraud Section leads the Criminal Division’s efforts to combat health care fraud through the Health Care Fraud Strike Force Program. Since March 2007, this program, currently comprised of 9 strike forces operating in 27 federal districts, has charged more than 5,800 defendants who collectively have billed federal health care programs and private insurers more than $30 billion. In addition, the Centers for Medicare & Medicaid Services, working in conjunction with HHS-OIG, are taking steps to hold providers accountable for their involvement in health care fraud schemes. More information can be found at www.justice.gov/criminal-fraud/health-care-fraud-unit.

    MIL OSI USA News –

  • MIL-OSI Europe: Bulgaria ready to use the euro from 1 January 2026

    Source: European Union 2

    The EU has given the final green light for Bulgaria to introduce the euro on 1 January 2026. Joining the euro area will bring tangible benefits to Bulgarian citizens and businesses: no more currency exchange costs, increased price transparency, easier cross-border payments and access to finance.

    MIL OSI Europe News –

  • MIL-OSI Security: Two California Residents Plead Guilty in Connection with $16M Hospice Fraud Scheme and Money Laundering Scheme

    Source: United States Attorneys General

    Two California residents pleaded guilty yesterday in connection with their roles in defrauding Medicare of nearly $16 million through sham hospice companies and to laundering the proceeds of the fraud as part of a multi-year scheme.

    According to court documents, Karpis Srapyan, 35, of Winnetka, California, conspired with others, including co-defendants Petros Fichidzhyan and Juan Carlos Esparza, to bill Medicare for hospice services that were not medically necessary and never provided. To conduct their fraudulent scheme, they used a series of four sham hospice companies: one owned by Esparza and the other three owned by foreign nationals but controlled by the defendants. Srapyan and his co-defendants concealed the scheme by using foreign nationals’ personal identifying information to open bank accounts, submit information to Medicare, and sign property leases. They also misappropriated names and other identifying information of several doctors, two of whom were deceased, to fraudulently bill Medicare for purported hospice services. In total, Medicare paid the fake hospice companies nearly $16 million.

    Fichidzhyan, Esparza, and Srapyan worked with others to launder the fraudulent proceeds from their hospice scheme. Susanna Harutyunyan, 39, of Winnetka, was aware that her husband and co-defendant Mihran Panosyan was involved in illegal activity with Srapyan and Fichidzhyan. As part of the money laundering scheme, Harutyunyan and her co-defendants maintained fraudulent identification documents, bank documents, checkbooks, and credit and debit cards in the names of purported foreign owners in the residence where she and Panosyan lived and another residence that was owned in her name. Srapyan conducted dozens of financial transactions, totaling approximately $3.2 million, moving funds between accounts in the names of the sham hospice companies, accounts in the names of foreign nationals that were controlled by the defendants, and other accounts involved in the money laundering scheme. Harutyunyan knowingly spent fraudulent proceeds on personal expenses, including payments for a BMW automobile.

    Srapyan pleaded guilty to conspiracy to commit health care fraud and money laundering and is scheduled to be sentenced on Oct. 6. He faces a maximum penalty of 20 years in prison. Harutyunyan pleaded guilty to money laundering and is scheduled to be sentenced on Nov. 17; she faces a maximum penalty of 10 years in prison. A federal district court judge will determine their sentences after considering the U.S. Sentencing Guidelines and other statutory factors. Harutyunyan faces deportation.

    Co-defendant Petros Fichidzhyan previously pleaded guilty to health care fraud, aggravated identity theft, and money laundering. In May, Fichidzhyan was sentenced to 12 years in prison. Co-defendant Mihran Panosyan pleaded guilty to money laundering in June and is scheduled to be sentenced Sept. 8. Co-defendant Juan Carlos Esparza’s change of plea hearing is scheduled for July 14.

    The guilty pleas today are the most recent convictions in the Justice Department’s ongoing effort to combat hospice fraud in the greater Los Angeles area. Last year, a doctor was convicted at trial for his role in a scheme to bill Medicare for hospice services patients did not need, and two other defendants were sentenced for their roles in a hospice fraud scheme.  

    Matthew R. Galeotti, Head of the Justice Department’s Criminal Division, Assistant Director in Charge Akil Davis of the FBI Los Angeles Field Office, and Deputy Inspector General for Investigations Christian J. Schrank of the U.S. Department of Health and Human Services Office of the Inspector General (HHS-OIG) made the announcement.

    The FBI and HHS-OIG are investigating the case.

    Trial Attorneys Michael Bacharach, Sarah E. Edwards, and Allison L. McGuire of the Criminal Division’s Fraud Section are prosecuting the case, and Assistant U.S. Attorney Tara B. Vavere for the Central District of California is handling asset forfeiture.

    The Fraud Section leads the Criminal Division’s efforts to combat health care fraud through the Health Care Fraud Strike Force Program. Since March 2007, this program, currently comprised of 9 strike forces operating in 27 federal districts, has charged more than 5,800 defendants who collectively have billed federal health care programs and private insurers more than $30 billion. In addition, the Centers for Medicare & Medicaid Services, working in conjunction with HHS-OIG, are taking steps to hold providers accountable for their involvement in health care fraud schemes. More information can be found at www.justice.gov/criminal-fraud/health-care-fraud-unit.

    MIL Security OSI –

  • MIL-OSI Security: Group convicted after Russian-ordered arson attack in London

    Source: United Kingdom London Metropolitan Police

    Five men have been convicted for their involvement in a Russian-ordered arson attack on a London warehouse full of supplies destined for Ukraine.

    Approximately £1 million of damage was caused after two units in an industrial estate in Leyton were deliberately set alight on 20 March last year.

    An investigation led by the Met’s Counter Terrorism Command found that Dylan Earl, aged 21, established contact with the Wagner Group, a private military organisation that acts on behalf of the Russian state, in 2023.

    Earl then recruited a group of men to set fire to the Leyton warehouse and organised surveillance of two businesses in Mayfair in preparation for further arson attacks.

    Commander Dominic Murphy, head of the Met’s Counter Terrorism Command, said; “This case is clear example of an organisation linked to the Russian state using ‘proxies’ – in this case British men – to carry out very serious criminal activity in this country on their behalf.

    “The ringleaders – Earl and Reeves – willingly acted as hostile agents on behalf of the Russian state. I am pleased that, working closely with the Crown Prosecution Service, we were able to use the new National Security Act legislation, which meant the severity of Earl and Reeves’s offending was reflected in the charges they faced.

    “The warehouse arson put members of the public at great risk, and it was only by good fortune nobody was seriously injured or worse. Those involved showed little or no regard for the potential impact of their actions on the UK’s wider security. Seemingly motivated by the promise of money, they were prepared to commit criminal acts on behalf of Russia.

    “I hope these convictions send a strong warning of the very serious consequences of committing offences on behalf of a foreign country.”

    The businesses based in the warehouses damaged by the arson were both Ukrainian-owned.

    The fire was initially investigated by local Met officers in Waltham Forest. However, after officers became aware that another warehouse belonging to the same Ukrainian company was also subject to an arson attack in Madrid, Spain, detectives from the Met’s Counter Terrorism Command took over the investigation.

    Met counter terrorism detectives then worked quickly to identify the individuals involved, which led them to suspect that Earl was the architect of the plot.

    Earl was the first to be arrested in a B&Q car park in Hinckley, Leicestershire, on 10 April 2024. Analysis of his mobile phone revealed his contact with the Wagner Group on Telegram, via an account with the usernames ‘Privet Bot’ and ‘Lucky Strike’.

    In total, detectives extracted 56GB of data from Earl’s phone including, 5702 instant messages, 1244 e-mails, 51528 images, 3629 videos, 183 documents and 4840 social media files; some of the content required translation from Russian.

    The swift investigation was crucial in preventing Earl and others from carrying out further arson attacks at two premises in Mayfair – evidence of which was found by officers following his arrest. Messages recovered from Earl’s phone showed that reconnaissance had already been carried out and discussions were ongoing about the use of explosives to damage buildings.

    Detectives found that Earl was also raising the possibility of kidnapping the owner of the business, a Russian dissident, and “exiling him back to Russia to face prison.”

    Analysis of Earl’s Telegram messages showed the first person he recruited for the warehouse arson plot was Jake Reeves, who then recruited his friend Kojo Mensah to carry out the arson. In turn, Mensah recruited his friend Jakeem Rose. Ugnius Asmena was also recruited to take part.

    The investigation team established that three men – Mensah, Rose and Asmena met up on the evening of 20 March 2024 and travelled in a red Kia Picanto to the scene of the arson. Officers found evidence that Mensah filmed the warehouse being set alight and livestreamed it on Face Time to Earl and Reeves.

    Dmitrijus Paulauskas, a friend of Reeves, and Ashton Evans, who helped Earl supply drugs, were also charged as part of the investigation as social media messages allegedly showed they were both aware of the arson attack and the planned offences in Mayfair.

    On 8 July Mensah , 23 (03.06.02) from Thornton Heath, Rose 23 (24.05.02), of Croydon and Asmena, 21 (31.12.04) of no fixed address, were convicted of aggravated arson.

    Paul English 61 (02.10.63) from Roehampton was found not guilty of the same charge.

    Paulauskas 23 (02.01.02), of Croydon was found not guilty of two counts of failing to disclose information about terrorist acts.

    Evans 20 (11.01.2005) of Newport. Evans was found not guilty of the first count (relating to the Leyton arson) but guilty of the second count related to the plot to damage businesses in Mayfair.

    Rose previously pleaded guilty to having a bladed article in a public place (in relation to a knife he left at the scene of the arson in Leyton). Evans also previously pleaded guilty to possession with intent to supply Class A drugs.

    Earl 21 (17.02.04) of Elmesthorpe, Leicester, pleaded guilty to preparatory conduct, contrary to section 18 of the National Security Act (NSA) 2023, aggravated arson, possession with intent to supply Class A drugs and possession of criminal property.

    Reeves, 23 (20.10.01), of Croydon pleaded guilty to agreeing to accept a material benefit from a foreign intelligence service, contrary to section 17(2) and (11), NSA 2023, and aggravated arson.

    Earl and Reeves are the first people to be convicted of offences under the National Security Act, which came into legislation at the end of 2023.

    All the defendants will be sentenced at the Old Bailey at a later date.

    All the material is available to download here

    https://mps.box.com/s/xfydvnz3dfddzsqyi7mntuzen88u17z7

    MIL Security OSI –

  • MIL-OSI Security: Three Law Enforcement Personnel Injured After Horrific Shooting in McAllen Texas

    Source: US Department of Homeland Security

    Shooter was neutralized by brave law enforcement officers

    TEXAS – Yesterday morning, a gunman, preliminarily identified as Ryan Louis Mosqued, opened fire at the entrance of the United States Border Patrol (USBP) sector annex in McAllen, Texas.

    The suspect was neutralized by law enforcement who acted heroically to stop the shooter before there was any loss of life, however three were injured. A McAllen police officer was shot in the leg. Both a Border Patrol officer and Border Patrol employee also sustained injuries. All three were taken to the hospital in non-critical condition. This incident is being investigated by CBP’s Office of Professional Responsibility in coordination with the FBI.

    This attack comes as federal law enforcement is facing a staggering surge in assaults and politicians continue to vilify and attack law enforcement. Just yesterday Axios published a post quoting a democratic lawmaker saying: “Our own base is telling us that what we’re doing is not good enough … [that] there needs to be blood to grab the attention of the press and the public.”

    “Yesterday’s heinous and unprovoked attack in McAllen could have been a bloodbath if not for the fearless actions of Border Patrol and McAllen law enforcement,” said DHS Assistant Secretary Tricia McLaughlin. “This vile assault on our officers is a disgusting escalation fueled by toxic rhetoric vilifying those who protect our borders. This must end now, and those stoking this violence will face consequences.”

    ###

    MIL Security OSI –

  • MIL-OSI: Bell Wealth Partners Launches with Support of LPL Strategic Wealth Services

    Source: GlobeNewswire (MIL-OSI)

    SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that father and son financial advisors Robert Bell, II, AIF®, and Keegan Bell, AIF®, AAMS®, have launched a new independent practice, Bell Wealth Partners, through affiliation with LPL Financial’s supported independence model, LPL Strategic Wealth Services. The team reported serving approximately $450 million in advisory, brokerage and retirement plan assets* and joins LPL from Raymond James.

    Headquartered in Fairbanks, Alaska with an additional office in Medford, Ore., the ensemble practice has developed a strong reputation over the years for providing holistic experiences and personalized services to address each aspect of a client’s financial life. The Bells are managing partners of the firm and are joined by fellow advisor Tom Cook and client associates Renee Schoettle, Margarita Duran-Espino, Jamie Walker and Kirsten Bell, Robert’s wife.

    “We are all deeply invested in helping our clients work toward their financial goals,” Robert said. “We take the time to get to know each client on a personal level to better understand their financial aspirations, and we work with their accountants and attorneys to create a customized plan that is right for them. It’s our goal to help clients have happy, fulfilled lives, and we consider it our privilege and responsibility to help them with that.”

    Why they made the move to LPL Financial

    The transition to LPL Financial is underpinned by the team’s aspiration to augment client experiences and cater to the next generation of wealth.

    “We’re moving to LPL so we can add more value to the client experience as we seek new ways to go above and beyond,” Keegan said. “We want to be a one-stop shop—a center to help with a clients’ entire financial situation. This move allows us to really increase that value add and better take care of them, not just for them but for the next generation of wealth and the transfer to their beneficiaries.”

    The team was drawn to LPL’s comprehensive supported independence solution, LPL Strategic Wealth Services (SW), which combines the freedom and flexibility of entrepreneurship with hands-on business services and support to help practices thrive, both operationally and strategically. In addition to having access to LPL’s innovative wealth management platform and sophisticated resources, SW advisors benefit from a truly integrated service that includes simplified pricing, technology and dedicated support to launch their practice. Then, after the transition is complete, SW teams receive ongoing operations support managed by their team of experienced professionals including a business strategist, marketing partner, CFO and administrative assistant. Advisors have one point of contact, a dedicated team and priority access to advocacy and project management for complex business issues, ultimately allowing them to stay focused on the enduring needs of their clients and the culture and evolution of their practice.

    “Strategic Wealth Services was truly a differentiating factor in our decision to move,” Robert said. “We are joining a very niche group at LPL, which allows us to collaborate with others in the model and access a team of specialists, including high-net-worth and trust consultants. This move enables us to add an extra layer of planning and ensure we’re not just taking care of clients now, but their beneficiaries as well.”

    Scott Posner, LPL Managing Director, Business Development, said, “We welcome Robert, Keegan, Tom, Renee, Margarita, Jamie and Kirsten to the LPL community and congratulate them on going independent with LPL Strategic Wealth. Just as the Bell Wealth Partners team is committed to helping their clients work toward their fiscal goals, LPL provides advisors with innovative technology and sophisticated capabilities to help them provide an elevated client experience. We look forward to supporting Bell Wealth Partners for years to come.”

    Related

    Advisors, learn how LPL Financial can help take your business to the next level.

    About LPL Financial

    LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports nearly 29,000 financial advisors and the wealth management practices of approximately 1,200 financial institutions, servicing and custodying approximately $1.8 trillion in brokerage and advisory assets on behalf of approximately 7 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

    Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC.

    Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial. Bell Wealth Partners and LPL are separate entities.

    We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

    *Value approximated based on asset and holding details provided to LPL from end of year, 2024.

    Media Contact: 
    Media.relations@LPLFinancial.com 

    Tracking #760446

    The MIL Network –

  • MIL-OSI: Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

    Source: GlobeNewswire (MIL-OSI)

    PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) — FN Media Group News Commentary – The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors are driving this expansion, including rising cancer incidence, advancements in therapies like precision medicine and immunotherapy, and increased investment in research and development. A report from Grand View Research said that the global breakthrough therapy designation market size is projected to grow at a CAGR of 14.2% through 2030. It is a process designed to escalate the development and assessment of sanctioning of drugs & biologics that are proposed for treating severe diseases, whereas primary clinical evidence notifies that the drug determines considerable enhancement over existing therapy on a clinically significant endpoint. Furthermore, the BT (Breakthrough) designation lets pharma companies hasten the developmental process by offering additional support and assistance from the FDA and making medications available to the public faster. The report continued: “Apart from breakthrough designation therapy, there are some important tools, all of which have been in place for many years, such as fast-track designation, accelerated approval, and priority review. All of these are inclined toward approving drugs used to treat serious disorders. Although these processes can reduce a drug’s time to market, standard clinical testing is required for the development process, which usually involves three phases of large-scale and controlled trials.” Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech®Inc. (NASDAQ: ONCY) (TSX: ONC), Mustang Bio, Inc. (NASDAQ: MBIO), Verastem Oncology (NASDAQ: VSTM), Cardiff Oncology, Inc. (NASDAQ: CRDF), AstraZeneca PLC (NASDAQ: AZN).

    Grand View Research continued: “The increasing prevalence of life-threatening conditions and the necessity for the rapid development of pipeline drugs are also some factors that propel the breakthrough therapy drug market. This is primarily driven by the significant unmet need for effective treatments for severe conditions currently available. Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often undergo less extensive clinical trials, which is a direct consequence of their market designation. The FDA’s enhanced support for small-scale industries in research and development, including increased funding and expedited drug approval processes, is further stimulating the market for breakthrough therapy drugs. Collectively, these elements are pushing the breakthrough therapy drug market forward. Further, innovative gene and cell therapies are offering new treatment decisions for previously untreatable illnesses, mainly drifting to more breakthrough therapy designations. Moreover, the regulatory support agencies are streamlining processes and offering assistance for breakthrough therapies to speed up their development and sanction. Another aspect leading the breakthrough therapy designations is the cross-sector collaborations between academic institutions, pharmaceutical companies, and research institutes that are lifting the upgradation and the advancement of new breakthrough therapies completely.”

    Oncolytics Biotech®Inc. (NASDAQ: ONCY) (TSX: ONC) Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

    • Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark
    • Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication
    • Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile

    — Oncolytics Biotech ® Inc. ($ONCY $ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company’s intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies.

    “We are no longer in the business of funding proof-of-concept studies,” said Jared Kelly, Chief Executive Officer of Oncolytics. “We have meaningful clinical data in hand—not just signals. The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials. We will use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology.”

    Results from two completed first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) trials demonstrate a strong and consistent efficacy signal showing extremely rare 2-year overall survival rates of 21.9% vs. 9.2% based on pooled data from over 100 patients across two studies evaluating pelareorep combined with a chemotherapy backbone. In addition, a best-in-class 62% objective response rate (ORR) was observed in a single-arm study of pelareorep in combination with a chemotherapy backbone and a checkpoint inhibitor in 13 evaluable patients. These results collectively represent promising efficacy for a therapeutic regimen that includes an immunotherapy in this difficult-to-treat cancer. Currently, there are no approved immunotherapies for first-line treatment of mPDAC…

    …Pelareorep’s clinical activity in HR+/HER2- metastatic breast cancer – a large indication with continued significant unmet medical need and no currently approved immunotherapies – has been demonstrated in two randomized phase 2 studies, both of which showed a median overall survival (mOS) benefit of greater than 10 months compared to standard-of-care chemotherapy (IND.213 mOS: 21.0 vs. 10.8 months; BRACELET-1 mOS: not statistically reached; conservative estimate = 32.1 months vs. 18.2 months). In the randomized, controlled BRACELET-1 study, pelareorep combined with paclitaxel yielded a 12.1-month median progression-free survival (PFS) compared to 6.4 months in the paclitaxel alone control arm.

    “Pelareorep represents a tipping point for immunotherapy in cold tumors,” said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. “It is delivering consistent immunologic and clinical responses in multiple tumor types. Most impressively, pelareorep activates the immune system to produce clinical benefits in cancers that are typically unresponsive to immunotherapies like mPDAC and unresectable HR+/HER2- breast cancer, creating new oncology entry points for immune-based combination therapies.” CONTINUED… Read these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

    Other recent oncology developments in the biotech industry of note include:

    Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, recently announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to Mustang for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma (GBM).

    The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain incentives, such as tax credits toward the cost of clinical trials upon approval and prescription drug user fee waivers. If a product receives Orphan Drug Status from the FDA, that product is entitled to seven years of market exclusivity for the disease in which it has Orphan Drug designation, which is independent from intellectual property protection.

    Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, recently announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published online in Nature Medicine. The full manuscript, titled “Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial,” was the first-in-human study to evaluate the safety, tolerability, and efficacy of avutometinib in combination with defactinib in patients with low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and other solid tumor types.

    “The FRAME study was the early foundation for the recent FDA approval of avutometinib plus defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer and we are pleased to see that the mature data set continues to show the safety and tolerability of this combination therapy,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “This supports our ongoing commitment to advancing our research into the combination for use in other solid tumors, including RAMP 205 in first-line metastatic pancreatic cancer.”

    Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced the company has appointed Roger Sidhu, MD, as Chief Medical Officer. Dr. Sidhu is a veteran executive and clinician with over 20 years of experience and a strong track record of success in oncology research, development, and regulatory strategy. Dr. Sidhu succeeds Dr. Fairooz Kabbinavar who will remain with the company in an advisory role. The company also announced it will share additional clinical data from its lead program in RAS-mutated mCRC on July 29, 2025.

    “We are pleased to welcome Dr. Sidhu to lead the clinical program for onvansertib through the next phase of development. Dr. Sidhu is a respected clinician and seasoned executive with a proven track record of advancing innovative therapies through late-stage clinical development across multiple therapeutic areas including in first-line mCRC. As we move forward, we thank Dr. Kabbinavar for his leadership in progressing onvansertib’s clinical development across multiple tumor types,” said Mark Erlander, Chief Executive Officer of Cardiff Oncology. “In addition to today’s medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset.”

    AstraZeneca PLC (NASDAQ: AZN)‘s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

    The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine.

    In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm.

    About FN Media Group:

    At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #pressreleases #tickertagpressreleases

    Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia

    Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup

    Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/

    DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech® Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

    This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

    Contact Information:

    Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757 

    SOURCE: FN Media Group

    The MIL Network –

  • MIL-OSI: Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

    Source: GlobeNewswire (MIL-OSI)

    PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) — FN Media Group News Commentary – The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors are driving this expansion, including rising cancer incidence, advancements in therapies like precision medicine and immunotherapy, and increased investment in research and development. A report from Grand View Research said that the global breakthrough therapy designation market size is projected to grow at a CAGR of 14.2% through 2030. It is a process designed to escalate the development and assessment of sanctioning of drugs & biologics that are proposed for treating severe diseases, whereas primary clinical evidence notifies that the drug determines considerable enhancement over existing therapy on a clinically significant endpoint. Furthermore, the BT (Breakthrough) designation lets pharma companies hasten the developmental process by offering additional support and assistance from the FDA and making medications available to the public faster. The report continued: “Apart from breakthrough designation therapy, there are some important tools, all of which have been in place for many years, such as fast-track designation, accelerated approval, and priority review. All of these are inclined toward approving drugs used to treat serious disorders. Although these processes can reduce a drug’s time to market, standard clinical testing is required for the development process, which usually involves three phases of large-scale and controlled trials.” Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech®Inc. (NASDAQ: ONCY) (TSX: ONC), Mustang Bio, Inc. (NASDAQ: MBIO), Verastem Oncology (NASDAQ: VSTM), Cardiff Oncology, Inc. (NASDAQ: CRDF), AstraZeneca PLC (NASDAQ: AZN).

    Grand View Research continued: “The increasing prevalence of life-threatening conditions and the necessity for the rapid development of pipeline drugs are also some factors that propel the breakthrough therapy drug market. This is primarily driven by the significant unmet need for effective treatments for severe conditions currently available. Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often undergo less extensive clinical trials, which is a direct consequence of their market designation. The FDA’s enhanced support for small-scale industries in research and development, including increased funding and expedited drug approval processes, is further stimulating the market for breakthrough therapy drugs. Collectively, these elements are pushing the breakthrough therapy drug market forward. Further, innovative gene and cell therapies are offering new treatment decisions for previously untreatable illnesses, mainly drifting to more breakthrough therapy designations. Moreover, the regulatory support agencies are streamlining processes and offering assistance for breakthrough therapies to speed up their development and sanction. Another aspect leading the breakthrough therapy designations is the cross-sector collaborations between academic institutions, pharmaceutical companies, and research institutes that are lifting the upgradation and the advancement of new breakthrough therapies completely.”

    Oncolytics Biotech®Inc. (NASDAQ: ONCY) (TSX: ONC) Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

    • Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark
    • Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication
    • Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile

    — Oncolytics Biotech ® Inc. ($ONCY $ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company’s intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies.

    “We are no longer in the business of funding proof-of-concept studies,” said Jared Kelly, Chief Executive Officer of Oncolytics. “We have meaningful clinical data in hand—not just signals. The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials. We will use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology.”

    Results from two completed first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) trials demonstrate a strong and consistent efficacy signal showing extremely rare 2-year overall survival rates of 21.9% vs. 9.2% based on pooled data from over 100 patients across two studies evaluating pelareorep combined with a chemotherapy backbone. In addition, a best-in-class 62% objective response rate (ORR) was observed in a single-arm study of pelareorep in combination with a chemotherapy backbone and a checkpoint inhibitor in 13 evaluable patients. These results collectively represent promising efficacy for a therapeutic regimen that includes an immunotherapy in this difficult-to-treat cancer. Currently, there are no approved immunotherapies for first-line treatment of mPDAC…

    …Pelareorep’s clinical activity in HR+/HER2- metastatic breast cancer – a large indication with continued significant unmet medical need and no currently approved immunotherapies – has been demonstrated in two randomized phase 2 studies, both of which showed a median overall survival (mOS) benefit of greater than 10 months compared to standard-of-care chemotherapy (IND.213 mOS: 21.0 vs. 10.8 months; BRACELET-1 mOS: not statistically reached; conservative estimate = 32.1 months vs. 18.2 months). In the randomized, controlled BRACELET-1 study, pelareorep combined with paclitaxel yielded a 12.1-month median progression-free survival (PFS) compared to 6.4 months in the paclitaxel alone control arm.

    “Pelareorep represents a tipping point for immunotherapy in cold tumors,” said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. “It is delivering consistent immunologic and clinical responses in multiple tumor types. Most impressively, pelareorep activates the immune system to produce clinical benefits in cancers that are typically unresponsive to immunotherapies like mPDAC and unresectable HR+/HER2- breast cancer, creating new oncology entry points for immune-based combination therapies.” CONTINUED… Read these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

    Other recent oncology developments in the biotech industry of note include:

    Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, recently announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to Mustang for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma (GBM).

    The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain incentives, such as tax credits toward the cost of clinical trials upon approval and prescription drug user fee waivers. If a product receives Orphan Drug Status from the FDA, that product is entitled to seven years of market exclusivity for the disease in which it has Orphan Drug designation, which is independent from intellectual property protection.

    Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, recently announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published online in Nature Medicine. The full manuscript, titled “Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial,” was the first-in-human study to evaluate the safety, tolerability, and efficacy of avutometinib in combination with defactinib in patients with low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and other solid tumor types.

    “The FRAME study was the early foundation for the recent FDA approval of avutometinib plus defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer and we are pleased to see that the mature data set continues to show the safety and tolerability of this combination therapy,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “This supports our ongoing commitment to advancing our research into the combination for use in other solid tumors, including RAMP 205 in first-line metastatic pancreatic cancer.”

    Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced the company has appointed Roger Sidhu, MD, as Chief Medical Officer. Dr. Sidhu is a veteran executive and clinician with over 20 years of experience and a strong track record of success in oncology research, development, and regulatory strategy. Dr. Sidhu succeeds Dr. Fairooz Kabbinavar who will remain with the company in an advisory role. The company also announced it will share additional clinical data from its lead program in RAS-mutated mCRC on July 29, 2025.

    “We are pleased to welcome Dr. Sidhu to lead the clinical program for onvansertib through the next phase of development. Dr. Sidhu is a respected clinician and seasoned executive with a proven track record of advancing innovative therapies through late-stage clinical development across multiple therapeutic areas including in first-line mCRC. As we move forward, we thank Dr. Kabbinavar for his leadership in progressing onvansertib’s clinical development across multiple tumor types,” said Mark Erlander, Chief Executive Officer of Cardiff Oncology. “In addition to today’s medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset.”

    AstraZeneca PLC (NASDAQ: AZN)‘s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

    The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine.

    In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm.

    About FN Media Group:

    At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies. #pressreleases #tickertagpressreleases

    Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia

    Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup

    Follow us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/

    DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech® Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

    This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

    Contact Information:

    Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757 

    SOURCE: FN Media Group

    The MIL Network –

  • MIL-OSI: Primech A&P, a Subsidiary of Primech Holdings, Secures Major Contract Extension Worth Over $8.3 Million

    Source: GlobeNewswire (MIL-OSI)

    SINGAPORE, July 08, 2025 (GLOBE NEWSWIRE) — Primech A & P, a subsidiary of Primech Holdings Limited (the “Company”) (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced a 2-year contract extension valued at S$10,650,000 (US$8.3 million) providing comprehensive cleaning services at a renowned institution in Singapore.

    This contract renewal, a significant revenue contribution for Primech Holdings’ award-winning facility services subsidiary, reinforces Primech A & P’s competitive positioning in Singapore’s institutional cleaning market. Primech A & P’s proven track record of delivering reliable, high-touch facilities services enabled the Company to retain major institutional clients and generate predictable, recurring revenue streams.

    Ken Chang, Head of Operations at Primech A & P, stated, “This S$10.65 million contract extension validates our strategic focus on high-value institutional partnerships and demonstrates the strength of our service delivery model. The client’s decision to renew for an additional two years provides us with strong revenue visibility and reflects our ability to exceed performance expectations consistently. Primech A & P is a trusted partner in Singapore’s premium facility services market, and contract wins such as this support our continued growth trajectory.”

    About Primech Holdings Limited
     
    Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit www.primechholdings.com.    

    Forward-Looking Statements

    Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

    Company Contact:
     Email: ir@primech.com.sg

    Investor Relations Contact:        
    Matthew Abenante, IRC
    President
    Strategic Investor Relations, LLC
    Tel: 347-947-2093
    Email: matthew@strategic-ir.com

    The MIL Network –

  • MIL-OSI: Primech A&P, a Subsidiary of Primech Holdings, Secures Major Contract Extension Worth Over $8.3 Million

    Source: GlobeNewswire (MIL-OSI)

    SINGAPORE, July 08, 2025 (GLOBE NEWSWIRE) — Primech A & P, a subsidiary of Primech Holdings Limited (the “Company”) (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced a 2-year contract extension valued at S$10,650,000 (US$8.3 million) providing comprehensive cleaning services at a renowned institution in Singapore.

    This contract renewal, a significant revenue contribution for Primech Holdings’ award-winning facility services subsidiary, reinforces Primech A & P’s competitive positioning in Singapore’s institutional cleaning market. Primech A & P’s proven track record of delivering reliable, high-touch facilities services enabled the Company to retain major institutional clients and generate predictable, recurring revenue streams.

    Ken Chang, Head of Operations at Primech A & P, stated, “This S$10.65 million contract extension validates our strategic focus on high-value institutional partnerships and demonstrates the strength of our service delivery model. The client’s decision to renew for an additional two years provides us with strong revenue visibility and reflects our ability to exceed performance expectations consistently. Primech A & P is a trusted partner in Singapore’s premium facility services market, and contract wins such as this support our continued growth trajectory.”

    About Primech Holdings Limited
     
    Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit www.primechholdings.com.    

    Forward-Looking Statements

    Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

    Company Contact:
     Email: ir@primech.com.sg

    Investor Relations Contact:        
    Matthew Abenante, IRC
    President
    Strategic Investor Relations, LLC
    Tel: 347-947-2093
    Email: matthew@strategic-ir.com

    The MIL Network –

  • MIL-OSI: Primech A&P, a Subsidiary of Primech Holdings, Secures Major Contract Extension Worth Over $8.3 Million

    Source: GlobeNewswire (MIL-OSI)

    SINGAPORE, July 08, 2025 (GLOBE NEWSWIRE) — Primech A & P, a subsidiary of Primech Holdings Limited (the “Company”) (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced a 2-year contract extension valued at S$10,650,000 (US$8.3 million) providing comprehensive cleaning services at a renowned institution in Singapore.

    This contract renewal, a significant revenue contribution for Primech Holdings’ award-winning facility services subsidiary, reinforces Primech A & P’s competitive positioning in Singapore’s institutional cleaning market. Primech A & P’s proven track record of delivering reliable, high-touch facilities services enabled the Company to retain major institutional clients and generate predictable, recurring revenue streams.

    Ken Chang, Head of Operations at Primech A & P, stated, “This S$10.65 million contract extension validates our strategic focus on high-value institutional partnerships and demonstrates the strength of our service delivery model. The client’s decision to renew for an additional two years provides us with strong revenue visibility and reflects our ability to exceed performance expectations consistently. Primech A & P is a trusted partner in Singapore’s premium facility services market, and contract wins such as this support our continued growth trajectory.”

    About Primech Holdings Limited
     
    Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit www.primechholdings.com.    

    Forward-Looking Statements

    Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

    Company Contact:
     Email: ir@primech.com.sg

    Investor Relations Contact:        
    Matthew Abenante, IRC
    President
    Strategic Investor Relations, LLC
    Tel: 347-947-2093
    Email: matthew@strategic-ir.com

    The MIL Network –

  • MIL-OSI: Primech A&P, a Subsidiary of Primech Holdings, Secures Major Contract Extension Worth Over $8.3 Million

    Source: GlobeNewswire (MIL-OSI)

    SINGAPORE, July 08, 2025 (GLOBE NEWSWIRE) — Primech A & P, a subsidiary of Primech Holdings Limited (the “Company”) (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced a 2-year contract extension valued at S$10,650,000 (US$8.3 million) providing comprehensive cleaning services at a renowned institution in Singapore.

    This contract renewal, a significant revenue contribution for Primech Holdings’ award-winning facility services subsidiary, reinforces Primech A & P’s competitive positioning in Singapore’s institutional cleaning market. Primech A & P’s proven track record of delivering reliable, high-touch facilities services enabled the Company to retain major institutional clients and generate predictable, recurring revenue streams.

    Ken Chang, Head of Operations at Primech A & P, stated, “This S$10.65 million contract extension validates our strategic focus on high-value institutional partnerships and demonstrates the strength of our service delivery model. The client’s decision to renew for an additional two years provides us with strong revenue visibility and reflects our ability to exceed performance expectations consistently. Primech A & P is a trusted partner in Singapore’s premium facility services market, and contract wins such as this support our continued growth trajectory.”

    About Primech Holdings Limited
     
    Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit www.primechholdings.com.    

    Forward-Looking Statements

    Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

    Company Contact:
     Email: ir@primech.com.sg

    Investor Relations Contact:        
    Matthew Abenante, IRC
    President
    Strategic Investor Relations, LLC
    Tel: 347-947-2093
    Email: matthew@strategic-ir.com

    The MIL Network –

  • MIL-OSI: Correction: Form 8.3 – Unite Group Plc

    Source: GlobeNewswire (MIL-OSI)

    AMENDED DISCLOSURE – PLEASE REFER TO SECTION 3(a)

    8.3

    PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
    A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
    Rule 8.3 of the Takeover Code (the “Code”)

    1.        KEY INFORMATION

    (a)   Full name of discloser: Rathbones Group Plc
    (b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
            The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    		  
    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
            Use a separate form for each offeror/offeree    		 The Unite Group Plc
    (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
    (e)   Date position held/dealing undertaken:
            For an opening position disclosure, state the latest practicable date prior to the disclosure    		 03/07/2025
    (f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
            If it is a cash offer or possible cash offer, state “N/A”    		 Yes

    2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

    If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

    (a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

    Class of relevant security: 25p Ord
      Interests Short positions
      Number % Number %
    (1)   Relevant securities owned and/or controlled: 724,161 0.14%    
    (2)   Cash-settled derivatives:        
    (3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        

            TOTAL:

    		 724,161 0.14%    

    All interests and all short positions should be disclosed.

    Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

    (b)      Rights to subscribe for new securities (including directors’ and other employee options)

    Class of relevant security in relation to which subscription right exists:  
    Details, including nature of the rights concerned and relevant percentages:  

    3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

    Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

    The currency of all prices and other monetary amounts should be stated.

    (a)        Purchases and sales

    Class of relevant security Purchase/sale Number of securities Price per unit
    25p Ordinary Shares Sale 500 823.6449p

    (b)        Cash-settled derivative transactions

    Class of relevant security Product description
    e.g. CFD    		 Nature of dealing
    e.g. opening/closing a long/short position, increasing/reducing a long/short position    		 Number of reference securities Price per unit
             

    (c)        Stock-settled derivative transactions (including options)

    (i)        Writing, selling, purchasing or varying

    Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
    e.g. American, European etc.    		 Expiry date Option money paid/ received per unit
                   

    (ii)        Exercise

    Class of relevant security Product description
    e.g. call option    		 Exercising/ exercised against Number of securities Exercise price per unit
             

    (d)        Other dealings (including subscribing for new securities)

    Class of relevant security Nature of dealing
    e.g. subscription, conversion    		 Details Price per unit (if applicable)
           

    4.        OTHER INFORMATION

    (a)        Indemnity and other dealing arrangements

    Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
    Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
    None

    (b)        Agreements, arrangements or understandings relating to options or derivatives

    Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
    (i)   the voting rights of any relevant securities under any option; or
    (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
    If there are no such agreements, arrangements or understandings, state “none”
    None

    (c)        Attachments

    Is a Supplemental Form 8 (Open Positions) attached? No
    Date of disclosure: 08/07/2025
    Contact name: Chinwe Enyi – Compliance Department
    Telephone number: 0151 243 7053

    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

    The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

    The Code can be viewed on the Panel’s website at.

    The MIL Network –

  • MIL-OSI: Xsolis’ AI-Driven Solution, New Features Evaluated in KLAS Second Look Report

    Source: GlobeNewswire (MIL-OSI)

    FRANKLIN, Tenn., July 08, 2025 (GLOBE NEWSWIRE) — Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers, was featured today in the KLAS Second Look Report, “Xsolis Platform 2025: Improving Utilization Management, Length of Stay & Denial Performance Through AI-Driven Offerings in the Mid-Revenue Cycle.” The KLAS Second Look Report focuses on how the customer experience has changed over the past four years, including as a result of enhancements made available within Dragonfly, the next generation of the company’s AI-driven platform.

    KLAS is an independent research organization that helps healthcare providers make informed technology decisions by offering accurate, honest, and impartial vendor performance information. KLAS interviewed Xsolis clients in early 2025 for a second look, and reports the following anonymized key findings:

    • Respondents report satisfaction within the Key Performance Indicators:
      • Supports integration goals
      • Product has needed functionality (delivers solutions as expected)
      • Executive involvement
      • Likely to recommend
    • 89% of KLAS-surveyed customers report using Xsolis’ AI technology to minimize preventable denials
    • 91% of respondents say they are Satisfied or Highly Satisfied with Overall Performance
    • 88% of respondents say they saw outcomes Immediately, Within 6 Months, or Within 6-12 Months
    • 78% engage in payer-provider communications through the Dragonfly platform
    • Respondents who have been on Xsolis’ AI-driven platform for more than one year report excitement about new updates and functionalities that are being offered as a result of Dragonfly
    • Respondents report the top reasons they selected the Xsolis platform as: advanced AI technology, excellent customer service, seamless EHR integration, and positive references
    • Respondents say the Xsolis platform has reduced the length of patient stays, saved on costs, and improved observation rates and denials rates

    “What has changed with our most recent KLAS survey effort is our expanded footprint and the problems Xsolis solves, including optimizing length-of-stay and increasing payer-provider collaboration, which have been critical in bringing relief to our clients,” said Joan Butters, CEO and co-founder of Xsolis. “As we enhance our solutions to deliver frictionless healthcare in meaningful, new ways for our clients, it is both validating and informative to learn their feedback as we continue to meet their evolving needs.”

    A Kaiser Family Foundation survey from 2023 revealed claims denials are up, with nearly one in five adults experiencing health insurance claim denials in the previous year. Adjudicating denials costs just under $20 billion a year, and around half of denials are ultimately overturned — a costly problem that can be improved with tools that accelerate payer-provider alignment. Late 2024 marked an inflection point for payer-provider friction and how it affects the patient experience, accelerating the need for transparency and reform.

    Xsolis was featured in a KLAS Top 20 Emerging Solutions Report and as one of the top five solutions for reducing the cost of care in 2022 and was listed in 2025 as No. 1 Best in KLAS for Physician Advisory Services for the fourth year. A payer client’s and provider client’s use of Xsolis’ shared platform was recognized in a 2023 KLAS Points of Light Case Study, which highlights successful payer-provider initiatives that lead to an improved patient experience.

    As a pioneer in the practical, effective application of AI in healthcare, Xsolis has been helping its clients make more informed medical necessity decisions during utilization reviews since 2013. Dragonfly represents the next generation of the company’s AI-driven platform and was launched in late 2024. The platform is powered by Predictive AI models, offers new Generative AI tools, and can be augmented with advanced analytic packages such as Navigate to reduce length of stay or Revenue Integrity Insights. Xsolis also offers Denials Management Services and Physician Advisory Services. To date, Xsolis’ solutions are used in more than 500 hospitals nationwide, with two-thirds having shared AI platform access with their networked health plans.

    To learn more about Xsolis, please visit: www.xsolis.com

    Download the KLAS Second Look Report here: https://www.xsolis.com/2025-klas-second-look-report/

    KLAS subscribers can access the report here: https://klasresearch.com/report/xsolis-platform-2025-improving-utilization-management-length-of-stay-and-denial-performance-through-ai-driven-offerings-in-the-mid-revenue-cycle/3746

    About Xsolis
    Xsolis is an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Dragonfly®, its AI-driven proprietary platform, is the first and only solution to use real-time predictive analytics to continuously assign an objective medical necessity score and assess the anticipated level of care for every patient, enabling more efficiency across the healthcare system. Xsolis is headquartered in Franklin, Tennessee. For more information, visit www.xsolis.com.

    About KLAS
    KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.

    The MIL Network –

  • MIL-OSI: BlockchainCloudMining Launches New Short-Term Contracts to Help Investors Capitalize on Crypto Market Volatility

    Source: GlobeNewswire (MIL-OSI)

    Miami, Florida, July 08, 2025 (GLOBE NEWSWIRE) — In response to a crypto market navigating a complex new cycle, BlockchainCloudMining, a leading global cloud mining platform, today announced the launch of a new suite of short-term, high-yield mining contracts. The new offerings are specifically designed to provide investors with a stable and predictable way to generate returns from their crypto assets amidst ongoing market volatility.

    The move comes as investors are shifting from speculative trading to more sustainable, long-term strategies. By offering contracts with fixed returns and short durations, BlockchainCloudMining aims to provide a low-risk channel for individuals to put their idle crypto assets to work. To encourage trial, the company is offering an instant $12 bonus to all new users upon registration.

    “Investors are moving beyond speculation and are now seeking sustainable value from their digital assets,” said the spokesperson for BlockchainCloudMining. “Our new short-term contracts are a direct answer to this demand. We are providing a transparent, low-risk channel for individuals to earn daily returns without the need for hardware or exposure to extreme market sentiment.”

    The new contracts are available immediately and offer several key advantages:

    • High Profitability: Designed for strong, predictable returns with dividends paid within 24 hours.
    • No Hidden Fees: The platform charges no management or service fees on its contracts.
    • Multi-Currency Support: Accepts deposits and pays out in over nine popular cryptocurrencies, including BTC, ETH, DOGE, SOL, USDC, USDT, XRP, LTC, and BCH.
      • Robust Security: The platform is protected by McAfee® and Cloudflare®, ensuring secure transactions and data protection with a 100% uptime guarantee.
      • Referral Program: A generous affiliate program allows users to earn up to $50,000 in referral bonuses.

    The new contract tiers launched today include:

    Contract Plan Investment Duration Total Payout
    WhatsMiner M66S $ 100 2 Days $ 106
    WhatsMiner M60 $ 500 7 Days $ 545.50
    Bitcoin Miner S21+ $ 1,000 14 Days $ 1,196
    ALPH Miner AL1 $ 3,000 20 Days $ 3,900
    ANTSPACE HK3 $ 10,000 35 Days $ 15,950
    Full Details on Site $ 33,000 40 Days $ 59,400

    Users can register for an account with an email address and purchase a contract to begin mining immediately. Payouts are delivered daily and can be withdrawn to a personal crypto wallet or reinvested into new contracts blockchian to compound returns.

    About BlockchainCloudMining:

    BlockchainCloudMining is a premier global platform for cryptocurrency cloud mining. The company provides a secure and transparent way for users to mine cryptocurrencies like Bitcoin, Dogecoin, and Litecoin through a global network of green energy-powered data centers. With a commitment to security and a 100% uptime guarantee, the platform helps investors worldwide convert idle assets into a continuous income stream.

    For more information or to register for an account, please visit the official website – https://blockchaincloudmining.com/xml/index.html#/

    Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

    The MIL Network –

  • MIL-OSI: Top Las Vegas Loan Officer Leaves CrossCountry Mortgage, Boomerangs Back to Rate

    Source: GlobeNewswire (MIL-OSI)

    LAS VEGAS, July 08, 2025 (GLOBE NEWSWIRE) — Rate, a leading fintech company, today announced the return of top-producing Las Vegas loan originator Jia Mei Wang, who has officially boomeranged back to the company after a stint at CrossCountry Mortgage.

    A seasoned mortgage professional since 2003, Wang originally spent six years with Rate before exploring other platforms. She now returns, citing the company’s unmatched technology and end-to-end support.

    “After spending over half a decade at Rate in years prior, I was confident returning would be the right move,” said Wang. “The company’s technology platform makes it easier to close loans efficiently, which is critical when you’re focused on building long-term client relationships.”

    In addition to her career as a loan originator, Wang is also President of the North America Shanghai Chamber of Commerce. Her decision to rejoin reflects the company’s continued strength in attracting and retaining top-tier talent focused on growth, service, and community leadership.

    “Jia Mei is one of the top-producing loan officers in Las Vegas, and we’re excited to have her back,” said John Stewart, Rate Chief Production Officer, West. “She’s sharp, experienced, and deeply committed to her clients. She knows what it takes to deliver, and we’re proud to support her as she serves clients in Las Vegas and beyond.”

    Her return expands Rate’s presence in Las Vegas and reinforces the company’s commitment to supporting high-performing originators with the tools, coaching, and infrastructure to thrive.

    About Rate

    Rate Companies is a leader in mortgage lending and digital financial services. Headquartered in Chicago, Rate has over 850 branches across all 50 states and Washington, D.C. Since its launch in 2000, Rate has helped more than 2 million homeowners with home purchase loans, refinances, and home equity loans. The company has cemented itself as an industry leader by introducing innovative technology, offering low rates, and delivering unparalleled customer service. Recent honors and awards include: a Best Mortgage Lender of 2025 by Fortune; Best Mortgage Lender of 2025 for First-Time Homebuyers by Forbes; a Best Mortgage Lender of 2025 for FHA Loans, Home Equity Loans, and Lower Credit Scores by NerdWallet; Best Mortgage Lender of 2025 for Digital Experience and Down Payment Assistance by Motley Fool; Chicago Agent Magazine’s Lender of the Year for seven consecutive years. Visit rate.com for more information.

    Contact

    press@rate.com

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d70400a2-ae37-4214-a50b-87ba39f77f09

    The MIL Network –

  • MIL-OSI: Gevo to Participate in Virtual Fireside Chat

    Source: GlobeNewswire (MIL-OSI)

    ENGLEWOOD, Colo., July 08, 2025 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) announced today that Leke Agiri, Gevo’s Chief Financial Officer, and Eric Frey, Gevo’s Vice President of Finance and Strategy, will participate in a virtual fireside chat on Wednesday, July 9, 2025 at 10:00am ET.

    Investors and other persons interested in participating in the event must register using the link below.

    Registration Link: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-gevo-LDnER-DQV-

    About Gevo

    Gevo is a next-generation diversified energy company committed to fueling America’s future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Gevo’s innovative technology can be used to make a variety of renewable products, including synthetic aviation fuel (“SAF”), motor fuels, chemicals, and other materials that provide U.S.-made solutions. By investing in the backbone of rural America, Gevo’s business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. Gevo owns and operates one of the largest dairy-based renewable natural gas (“RNG”) facilities in the United States, turning by-products into clean, reliable energy. We also operate an ethanol plant with an adjacent carbon capture and sequestration (“CCS”) facility, further solidifying America’s leadership in energy innovation. Additionally, Gevo owns the world’s first production facility for specialty alcohol-to-jet (“ATJ”) fuels and chemicals. Gevo’s market-driven “pay for performance” approach regarding carbon and other sustainability attributes, helps ensure value is delivered to our local economy. Through its Verity subsidiary, Gevo provides transparency, accountability, and efficiency in tracking, measuring and verifying various attributes throughout the supply chain. By strengthening rural economies, Gevo is working to secure a self-sufficient future and to make sure value is brought to the market.

    For more information, see www.gevo.com.

    Media Contact
    Heather Manuel
    Vice President of Stakeholder Engagement & Partnerships
    PR@gevo.com

    Investor Contact
    Eric Frey, PhD
    Vice President of Finance and Strategy
    IR@Gevo.com

    The MIL Network –

  • MIL-OSI: Blue Mantis to Empower Massachusetts Agencies with Advanced Cybersecurity Preparedness

    Source: GlobeNewswire (MIL-OSI)

    PORTSMOUTH, N.H., July 08, 2025 (GLOBE NEWSWIRE) — Blue Mantis, a leading provider of digital strategy and services specializing in managed services, cybersecurity and cloud solutions, today announced that it has been selected as a preferred vendor by the Commonwealth of Massachusetts to deliver Cyber Incident Response Plan (IRP) and Tabletop Exercise (TTX) services to state agencies as part of the State and Local Cybersecurity Grant Program. This federal grant program enables Blue Mantis to further its commitment to strengthening the Commonwealth’s overall cybersecurity posture at the state and local level.

    Empowering State Agencies to Build Resilience Against Cyber Threats
    With the growing sophistication and frequency of cyberattacks, state agencies face mounting pressure to safeguard sensitive data, maintain critical operations, and demonstrate compliance with evolving statutes and regulations. The Blue Mantis IRP and TTX program provides Massachusetts agencies with comprehensive, scalable, and actionable solutions for incident response planning and cyber readiness.

    Through this contract, agencies can access:

    • Custom-Tailored Cyber Incident Response Plans (IRPs): Developed in alignment with industry best practices (NIST, CISA), these plans provide clear protocols, role assignments, and communication strategies, ensuring agencies are equipped to respond effectively to cyber incidents.
    • Scenario-Based Tabletop Exercises (TTXs): Interactive exercises based on the MITRE ATT&CK® framework allow agencies to test and validate their incident response plans, uncover potential gaps, and enhance cross-team coordination.
    • Proven Methodologies and Expertise: Drawing on over 30 years of experience supporting public sector and enterprise organizations, Blue Mantis combines deep technical expertise with a collaborative, customer-first approach that prioritizes measurable outcomes.
    • Accelerated Service Delivery: With the capacity to support multiple agencies simultaneously and a streamlined engagement lifecycle, Blue Mantis ensures agencies receive timely, high-quality support tailored to their unique operational environments.
    • Alignment with Compliance and Security Standards: All services are designed to meet or exceed the Commonwealth’s information security policies, accessibility standards, and regulatory requirements.

    A Partnership Built on Experience and Results
    This initiative is supported by Blue Mantis’ partnership with the Executive Office of Technology Services & Security (EOTSS). Together, these organizations are ensuring that Commonwealth agencies have access to best-in-class cybersecurity services, driving greater resiliency and preparedness across the public sector.

    “Cybersecurity is a team sport, and protecting the Commonwealth’s agencies requires public-private collaboration, expertise, and unwavering commitment,” said Josh Dinneen, CEO of Blue Mantis. “Thanks to our partnership with EOTSS, Blue Mantis is uniquely positioned to help state agencies anticipate, withstand, and recover from cyber threats. Our IRP and TTX services empower agencies to achieve new levels of resilience, compliance, and confidence as they serve the people of Massachusetts.”

    Contract Highlights:

    • Statewide Availability: The contract streamlines procurement, allowing all Commonwealth agencies to quickly and cost-effectively access Blue Mantis IRP and TTX services.
    • Scalable Engagements: Blue Mantis supports projects of all sizes, from individual departments to enterprise-wide initiatives, delivering consistent quality and measurable improvements.
    • Track Record of Success: Blue Mantis brings a history of successful engagements with municipalities and public sector organizations across Massachusetts and beyond, helping clients respond to and recover from real-world cybersecurity incidents.
    • Strategic Advocacy: Partnership with EOTSS ensures alignment with the Commonwealth’s overarching cybersecurity objectives and priorities.

    For more information about Blue Mantis’ cybersecurity services and the IRP/TTX program, visit www.bluemantis.com.

    About Blue Mantis
    Blue Mantis is a security-first IT solutions and services provider with a 30+ year history of successfully helping clients achieve business modernization by applying next-generation technologies including managed services, cybersecurity, cloud and collaboration. Headquartered in Portsmouth, New Hampshire, with offices in Charlestown, Massachusetts, the company provides digital technology services and strategic guidance to ensure clients quickly adapt and grow through automation and innovation. Blue Mantis partners with more than 1,500 leading mid-market and enterprise organizations in a multitude of vertical industries and is backed by leading private equity firm, Recognize. For more information, please visit www.bluemantis.com.

    Inquiries:
    David Knox
    Director of Public Sector
    Blue Mantis
    david.knox@bluemantis.com
    (781) 987-2013

    The MIL Network –

  • MIL-OSI: Blue Mantis to Empower Massachusetts Agencies with Advanced Cybersecurity Preparedness

    Source: GlobeNewswire (MIL-OSI)

    PORTSMOUTH, N.H., July 08, 2025 (GLOBE NEWSWIRE) — Blue Mantis, a leading provider of digital strategy and services specializing in managed services, cybersecurity and cloud solutions, today announced that it has been selected as a preferred vendor by the Commonwealth of Massachusetts to deliver Cyber Incident Response Plan (IRP) and Tabletop Exercise (TTX) services to state agencies as part of the State and Local Cybersecurity Grant Program. This federal grant program enables Blue Mantis to further its commitment to strengthening the Commonwealth’s overall cybersecurity posture at the state and local level.

    Empowering State Agencies to Build Resilience Against Cyber Threats
    With the growing sophistication and frequency of cyberattacks, state agencies face mounting pressure to safeguard sensitive data, maintain critical operations, and demonstrate compliance with evolving statutes and regulations. The Blue Mantis IRP and TTX program provides Massachusetts agencies with comprehensive, scalable, and actionable solutions for incident response planning and cyber readiness.

    Through this contract, agencies can access:

    • Custom-Tailored Cyber Incident Response Plans (IRPs): Developed in alignment with industry best practices (NIST, CISA), these plans provide clear protocols, role assignments, and communication strategies, ensuring agencies are equipped to respond effectively to cyber incidents.
    • Scenario-Based Tabletop Exercises (TTXs): Interactive exercises based on the MITRE ATT&CK® framework allow agencies to test and validate their incident response plans, uncover potential gaps, and enhance cross-team coordination.
    • Proven Methodologies and Expertise: Drawing on over 30 years of experience supporting public sector and enterprise organizations, Blue Mantis combines deep technical expertise with a collaborative, customer-first approach that prioritizes measurable outcomes.
    • Accelerated Service Delivery: With the capacity to support multiple agencies simultaneously and a streamlined engagement lifecycle, Blue Mantis ensures agencies receive timely, high-quality support tailored to their unique operational environments.
    • Alignment with Compliance and Security Standards: All services are designed to meet or exceed the Commonwealth’s information security policies, accessibility standards, and regulatory requirements.

    A Partnership Built on Experience and Results
    This initiative is supported by Blue Mantis’ partnership with the Executive Office of Technology Services & Security (EOTSS). Together, these organizations are ensuring that Commonwealth agencies have access to best-in-class cybersecurity services, driving greater resiliency and preparedness across the public sector.

    “Cybersecurity is a team sport, and protecting the Commonwealth’s agencies requires public-private collaboration, expertise, and unwavering commitment,” said Josh Dinneen, CEO of Blue Mantis. “Thanks to our partnership with EOTSS, Blue Mantis is uniquely positioned to help state agencies anticipate, withstand, and recover from cyber threats. Our IRP and TTX services empower agencies to achieve new levels of resilience, compliance, and confidence as they serve the people of Massachusetts.”

    Contract Highlights:

    • Statewide Availability: The contract streamlines procurement, allowing all Commonwealth agencies to quickly and cost-effectively access Blue Mantis IRP and TTX services.
    • Scalable Engagements: Blue Mantis supports projects of all sizes, from individual departments to enterprise-wide initiatives, delivering consistent quality and measurable improvements.
    • Track Record of Success: Blue Mantis brings a history of successful engagements with municipalities and public sector organizations across Massachusetts and beyond, helping clients respond to and recover from real-world cybersecurity incidents.
    • Strategic Advocacy: Partnership with EOTSS ensures alignment with the Commonwealth’s overarching cybersecurity objectives and priorities.

    For more information about Blue Mantis’ cybersecurity services and the IRP/TTX program, visit www.bluemantis.com.

    About Blue Mantis
    Blue Mantis is a security-first IT solutions and services provider with a 30+ year history of successfully helping clients achieve business modernization by applying next-generation technologies including managed services, cybersecurity, cloud and collaboration. Headquartered in Portsmouth, New Hampshire, with offices in Charlestown, Massachusetts, the company provides digital technology services and strategic guidance to ensure clients quickly adapt and grow through automation and innovation. Blue Mantis partners with more than 1,500 leading mid-market and enterprise organizations in a multitude of vertical industries and is backed by leading private equity firm, Recognize. For more information, please visit www.bluemantis.com.

    Inquiries:
    David Knox
    Director of Public Sector
    Blue Mantis
    david.knox@bluemantis.com
    (781) 987-2013

    The MIL Network –

  • MIL-OSI: LPL Research Team Releases Midyear Outlook 2025: Pragmatic Optimism, Measured Expectations

    Source: GlobeNewswire (MIL-OSI)

    This annual report offers a comprehensive analysis of the economic and market environment, highlighting potential implications for investors and their portfolios

    SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC today released its Midyear Outlook 2025: Pragmatic Optimism, Measured Expectations. Setting the tone for the second half of 2025, this report offers a comprehensive analysis of the economic and market environment, highlighting potential implications for investors and their portfolios.

    The Midyear Outlook 2025 offers a grounded, data-driven view of where the economy and markets may be headed next. As we reach the halfway mark of the year, trends in income and savings underscore how markets are still recalibrating in response to persistent inflation, a more measured Federal Reserve stance, ongoing tariff uncertainties and the volatility that continues to ripple through global financial systems.

    “Investors and policymakers will need to carefully evaluate the true economic impact of these policy shifts,” said Marc Zabicki, Chief Investment Officer at LPL Financial. “The base-case view is an economy that will begin to show more definitive adverse effects from trade policy with slower labor demand, weaker growth and an uptick in inflation.”

    Key Highlights from the Midyear Outlook 2025

    • Uncertainty in Markets & Evolving Policy: In the second half of the year, delayed effects of trade policy are expected to slow economic growth, soften labor demand and push inflation slightly higher. This challenging backdrop will likely keep the Federal Reserve in a cautious holding pattern on monetary policy for an extended period.
    • The State of the U.S. Economy & Potential Risks: Debt concerns, trade uncertainty and a cautious Federal Reserve are likely to keep Treasury yields range-bound in the second half. With yields still elevated by historical standards, investors should focus on income generation through intermediate-term bonds. As the Fed eventually begins cutting short-term rates, declining cash yields will make bonds increasingly attractive for long-term income and portfolio stability.
    • Investment Strategies in More Volatile Markets: The stock market’s outlook for the second half of the year will hinge on trade talks, AI developments, interest rate swings and tax policy. With valuations already pricing in much of the good news, gains may be modest. While volatility is expected in a tough macro environment, market pullbacks could offer smart opportunities to selectively add to equity positions.
    • Potential Trends & Opportunities in the Second Half of 2025: With economic and policy uncertainty likely to persist, tactical portfolios should strike a balance between risk management and seizing emerging opportunities. Diversifying across asset classes, regions and alternatives can help enhance resilience. Staying alert during market volatility may present timely chances to add equity exposure at more favorable valuations.

    “There’s also a strong likelihood that policy-driven uncertainty is past its high-water mark, and as it recedes, stability should gradually return, bringing with it plenty of new investment opportunities,” Zabicki added. “The environment we see ahead calls for balancing risk mitigation with proactive positioning for long-term upside opportunities—if you know where to look.”

    Important Disclosures

    Please see the LPL Financial Research Midyear Outlook 2025 for additional description and disclosure.

    The opinions, statements and forecasts presented herein are general information only and are not intended to provide specific investment advice or recommendations for any individual. To determine which investment(s) may be appropriate for you, please consult your financial professional prior to investing.

    Any forward-looking statements including the economic forecasts may not develop as predicted and are subject to change based on future market and other conditions.

    All indexes are unmanaged and cannot be invested into directly.

    All performance referenced is historical and is not a guarantee of future results.

    Investing involves risk including the loss of principal. There is no guarantee that a diversified portfolio will enhance overall returns or outperform a non-diversified portfolio. Diversification does not protect against market risk.​ Alternative investments may not be suitable for all investors and should be considered as an investment for the risk capital portion of the investor’s portfolio. The strategies employed in the management of alternative investments may accelerate the velocity of potential losses.

    About LPL Financial

    LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports over 29,000 financial advisors and the wealth management practices of approximately 1,200 financial institutions, servicing and custodying approximately $1.8 trillion in brokerage and advisory assets on behalf of approximately 7 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

    Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment adviser and broker-dealer. Member FINRA/SIPC.

    Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

    We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

    Media Contact: 
    Media.relations@LPLFinancial.com 
    (402) 740-2047 

    Tracking #: 763507

    The MIL Network –

  • MIL-OSI: LPL Research Team Releases Midyear Outlook 2025: Pragmatic Optimism, Measured Expectations

    Source: GlobeNewswire (MIL-OSI)

    This annual report offers a comprehensive analysis of the economic and market environment, highlighting potential implications for investors and their portfolios

    SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC today released its Midyear Outlook 2025: Pragmatic Optimism, Measured Expectations. Setting the tone for the second half of 2025, this report offers a comprehensive analysis of the economic and market environment, highlighting potential implications for investors and their portfolios.

    The Midyear Outlook 2025 offers a grounded, data-driven view of where the economy and markets may be headed next. As we reach the halfway mark of the year, trends in income and savings underscore how markets are still recalibrating in response to persistent inflation, a more measured Federal Reserve stance, ongoing tariff uncertainties and the volatility that continues to ripple through global financial systems.

    “Investors and policymakers will need to carefully evaluate the true economic impact of these policy shifts,” said Marc Zabicki, Chief Investment Officer at LPL Financial. “The base-case view is an economy that will begin to show more definitive adverse effects from trade policy with slower labor demand, weaker growth and an uptick in inflation.”

    Key Highlights from the Midyear Outlook 2025

    • Uncertainty in Markets & Evolving Policy: In the second half of the year, delayed effects of trade policy are expected to slow economic growth, soften labor demand and push inflation slightly higher. This challenging backdrop will likely keep the Federal Reserve in a cautious holding pattern on monetary policy for an extended period.
    • The State of the U.S. Economy & Potential Risks: Debt concerns, trade uncertainty and a cautious Federal Reserve are likely to keep Treasury yields range-bound in the second half. With yields still elevated by historical standards, investors should focus on income generation through intermediate-term bonds. As the Fed eventually begins cutting short-term rates, declining cash yields will make bonds increasingly attractive for long-term income and portfolio stability.
    • Investment Strategies in More Volatile Markets: The stock market’s outlook for the second half of the year will hinge on trade talks, AI developments, interest rate swings and tax policy. With valuations already pricing in much of the good news, gains may be modest. While volatility is expected in a tough macro environment, market pullbacks could offer smart opportunities to selectively add to equity positions.
    • Potential Trends & Opportunities in the Second Half of 2025: With economic and policy uncertainty likely to persist, tactical portfolios should strike a balance between risk management and seizing emerging opportunities. Diversifying across asset classes, regions and alternatives can help enhance resilience. Staying alert during market volatility may present timely chances to add equity exposure at more favorable valuations.

    “There’s also a strong likelihood that policy-driven uncertainty is past its high-water mark, and as it recedes, stability should gradually return, bringing with it plenty of new investment opportunities,” Zabicki added. “The environment we see ahead calls for balancing risk mitigation with proactive positioning for long-term upside opportunities—if you know where to look.”

    Important Disclosures

    Please see the LPL Financial Research Midyear Outlook 2025 for additional description and disclosure.

    The opinions, statements and forecasts presented herein are general information only and are not intended to provide specific investment advice or recommendations for any individual. To determine which investment(s) may be appropriate for you, please consult your financial professional prior to investing.

    Any forward-looking statements including the economic forecasts may not develop as predicted and are subject to change based on future market and other conditions.

    All indexes are unmanaged and cannot be invested into directly.

    All performance referenced is historical and is not a guarantee of future results.

    Investing involves risk including the loss of principal. There is no guarantee that a diversified portfolio will enhance overall returns or outperform a non-diversified portfolio. Diversification does not protect against market risk.​ Alternative investments may not be suitable for all investors and should be considered as an investment for the risk capital portion of the investor’s portfolio. The strategies employed in the management of alternative investments may accelerate the velocity of potential losses.

    About LPL Financial

    LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports over 29,000 financial advisors and the wealth management practices of approximately 1,200 financial institutions, servicing and custodying approximately $1.8 trillion in brokerage and advisory assets on behalf of approximately 7 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

    Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment adviser and broker-dealer. Member FINRA/SIPC.

    Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

    We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

    Media Contact: 
    Media.relations@LPLFinancial.com 
    (402) 740-2047 

    Tracking #: 763507

    The MIL Network –

  • MIL-OSI: Zenolabs.AI CEO Rohan Sharma Launches First-of-its-Kind Equitable AI Trust Index and Releases Springer Book AI and the Boardroom

    Source: GlobeNewswire (MIL-OSI)

    SAN FRANCISCO, July 08, 2025 (GLOBE NEWSWIRE) — Amid growing concerns around AI transparency, fairness, and societal impact, Zenolabs.AI CEO Rohan Sharma today launched the Equitable AI Trust Index™—the first public framework scoring AI systems on democratic legitimacy, transparency, and civic accountability. The release aligns with Sharma’s Springer Nature book, AI and the Boardroom, recently featured in Directors Today.

    “Boards and policymakers urgently need a single, clear lens on AI risk,” Sharma said. “Our Index integrates NIST, OECD, and EU AI Act standards into a transparent, easy-to-use scoring system. For the first time, stakeholders gain immediate visibility into where algorithms are accountable—or critically falling short.”

    Why It Matters
    Recent surveys reveal 46% of users distrust AI and 64% of firms lack visibility into model risk. With the EU AI Act’s enforcement deadlines approaching in 2026, the Equitable AI Trust Index™ equips organizations with policy-ready tools to meet stringent transparency and accountability requirements, critical for responsible scaling across enterprises, cities, and governments.

    How the Index Works
    The Index offers a clear, actionable framework for assessing AI fairness and accountability:

    • Public Trust Metric: first-of-its-kind score measuring community trust in AI through public input.
    • Proactive Risk Alerts: real-time insights to ensure compliance with global standards, months ahead of deadlines.
    • Fairness Focus: prioritizes equity for underserved communities and public services.
    • Policy-Ready Reports: instantly generate EU AI Act, NIST, and OECD-aligned audit reports.

    About Rohan Sharma
    Sharma has led AI, data and digital programs at Apple, Disney and Thermo Fisher Scientific. A recognized authority on AI governance, Sharma advises Stanford Seed and UCLA Anderson, contributes regularly to Forbes and the World Economic Forum, and serves on advisory councils including Harvard Business Review and Frost C Sullivan. His TEDx Yale talk and peer-reviewed chapters on AI governance and ethics have reached global audiences from Hollywood to Washington, D.C.

    Equitable AI Trust Index™: Analysis of Major AI Models
    The first comprehensive assessment of leading AI models using the 11-point Index reveals a democratic-legitimacy crisis in AI governance:

    Key Findings
    Our analysis reveals a democratic legitimacy crisis in AI governance, with only 20% of leading models meeting exemplary civic trust standards.

    • 20%: of leading models meet exemplary civic trust standards
    • 59-point: governance gap between best and worst performing models
    • 90.9/100: highest overall trust score (Anthropic Claude)
    • 39.4/100: lowest overall trust score (OpenAI ChatGPT)

    Availability

    • AI and the Boardroom (ISBN 979-8-8688-0796-1) — available worldwide through Springer Nature and Amazon.

    Media Contact
    press@zenolabs.ai | +1 323 236 8723

    Press kit (headshot, logos, Index score chart): https://trustworthyaiindex.org/methodology

    Boilerplate
    The Equitable AI Trust Index™ is a public-good initiative maintained by Zenolabs.AI, created to make algorithmic trust measurable, transparent, and comparable. Zenolabs.AI is a venture studio dedicated to advancing responsible AI governance and public accountability.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b8acf08c-6b63-4c8d-af43-2e60e7cd6b63

    The MIL Network –